PortalPublikationenCirculating tumor cell isolation and diagnostics: toward rou...

Circulating tumor cell isolation and diagnostics: toward routine clinical use.

Standard

Circulating tumor cell isolation and diagnostics: toward routine clinical use. / van de Stolpe, Anja; Pantel, Klaus; Sleijfer, Stefan; Terstappen, Leon W; Toonder, den; Jaap, M J.

in: CANCER RES, Jahrgang 71, Nr. 18, 18, 2011, S. 5955-5960.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

van de Stolpe, A, Pantel, K, Sleijfer, S, Terstappen, LW, Toonder, D & Jaap, MJ 2011, 'Circulating tumor cell isolation and diagnostics: toward routine clinical use.', CANCER RES, Jg. 71, Nr. 18, 18, S. 5955-5960. <http://www.ncbi.nlm.nih.gov/pubmed/21896640?dopt=Citation>

APA

van de Stolpe, A., Pantel, K., Sleijfer, S., Terstappen, L. W., Toonder, D., & Jaap, M. J. (2011). Circulating tumor cell isolation and diagnostics: toward routine clinical use. CANCER RES, 71(18), 5955-5960. [18]. http://www.ncbi.nlm.nih.gov/pubmed/21896640?dopt=Citation

Vancouver

van de Stolpe A, Pantel K, Sleijfer S, Terstappen LW, Toonder D, Jaap MJ. Circulating tumor cell isolation and diagnostics: toward routine clinical use. CANCER RES. 2011;71(18):5955-5960. 18.

Bibtex

@article{be2ac599407042dfbd687a0a7aee53ff,
title = "Circulating tumor cell isolation and diagnostics: toward routine clinical use.",
abstract = "From February 7-11, 2011, the multidisciplinary Lorentz Workshop Circulating Tumor Cell (CTC) Isolation and Diagnostics: Toward Routine Clinical Use was held in Leiden (The Netherlands) to discuss progress and define challenges and potential solutions for development of clinically useful circulating tumor cell (CTC) diagnostics. CTCs, captured as {"}liquid biopsy{"} from blood, for counting and characterization using pathology and molecular assays, are expected to replace metastatic tissue biopsies to be used to predict drug response and resistance and to monitor therapy response and cancer recurrence. CTCs are highly heterogeneous; therefore, cancer type-specific isolation technologies, as well as complex clinical interpretation software, are required.",
keywords = "Humans, Neoplastic Cells, Circulating/*pathology, Neoplasms/*blood/*diagnosis/pathology, Humans, Neoplastic Cells, Circulating/*pathology, Neoplasms/*blood/*diagnosis/pathology",
author = "{van de Stolpe}, Anja and Klaus Pantel and Stefan Sleijfer and Terstappen, {Leon W} and den Toonder and Jaap, {M J}",
year = "2011",
language = "English",
volume = "71",
pages = "5955--5960",
journal = "CANCER RES",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "18",

}

RIS

TY - JOUR

T1 - Circulating tumor cell isolation and diagnostics: toward routine clinical use.

AU - van de Stolpe, Anja

AU - Pantel, Klaus

AU - Sleijfer, Stefan

AU - Terstappen, Leon W

AU - Toonder, den

AU - Jaap, M J

PY - 2011

Y1 - 2011

N2 - From February 7-11, 2011, the multidisciplinary Lorentz Workshop Circulating Tumor Cell (CTC) Isolation and Diagnostics: Toward Routine Clinical Use was held in Leiden (The Netherlands) to discuss progress and define challenges and potential solutions for development of clinically useful circulating tumor cell (CTC) diagnostics. CTCs, captured as "liquid biopsy" from blood, for counting and characterization using pathology and molecular assays, are expected to replace metastatic tissue biopsies to be used to predict drug response and resistance and to monitor therapy response and cancer recurrence. CTCs are highly heterogeneous; therefore, cancer type-specific isolation technologies, as well as complex clinical interpretation software, are required.

AB - From February 7-11, 2011, the multidisciplinary Lorentz Workshop Circulating Tumor Cell (CTC) Isolation and Diagnostics: Toward Routine Clinical Use was held in Leiden (The Netherlands) to discuss progress and define challenges and potential solutions for development of clinically useful circulating tumor cell (CTC) diagnostics. CTCs, captured as "liquid biopsy" from blood, for counting and characterization using pathology and molecular assays, are expected to replace metastatic tissue biopsies to be used to predict drug response and resistance and to monitor therapy response and cancer recurrence. CTCs are highly heterogeneous; therefore, cancer type-specific isolation technologies, as well as complex clinical interpretation software, are required.

KW - Humans

KW - Neoplastic Cells, Circulating/pathology

KW - Neoplasms/blood/diagnosis/pathology

KW - Humans

KW - Neoplastic Cells, Circulating/pathology

KW - Neoplasms/blood/diagnosis/pathology

M3 - SCORING: Journal article

VL - 71

SP - 5955

EP - 5960

JO - CANCER RES

JF - CANCER RES

SN - 0008-5472

IS - 18

M1 - 18

ER -